Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Danaher (NYSE:DHR) issued its quarterly earnings data on Tuesday. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15, Briefing.com reports. Danaher had a return on equity of 10.90% and a net margin of 16.94%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business earned $2.05 earnings per share. The business’s revenue was down 2.9% on a year-over-year basis.

Danaher Stock Performance

NYSE:DHR traded up $4.33 during midday trading on Thursday, reaching $270.09. 4,248,613 shares of the company traded hands, compared to its average volume of 2,922,813. The firm has a market capitalization of $200.05 billion, a price-to-earnings ratio of 45.04, a price-to-earnings-growth ratio of 4.11 and a beta of 0.83. The company has a fifty day moving average price of $254.89 and a 200 day moving average price of $248.67. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher has a twelve month low of $182.09 and a twelve month high of $276.31.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Insiders Place Their Bets

In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Rainer Blair sold 19,085 shares of the stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total value of $4,866,675.00. Following the completion of the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $29,578,725. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold 75,175 shares of company stock valued at $19,161,154 over the last three months. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday. TD Cowen upped their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays raised their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday. Jefferies Financial Group initiated coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Finally, Stifel Nicolaus increased their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.